Cerus Corporation
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William Greenman
- Full Time Employees
- 614
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1220 Concord Avenue Concord CA United States of America 94520
- IPO Date
- Jan 31, 1997
- CIK
- 0001020214
- Website
- cerus.com
- Similar Companies
- Business
- Cerus Corporation (Nasdaq: CERS), headquartered in Concord, California and founded in 1991, develops and commercializes the INTERCEPT Blood System, a pathogen reduction technology designed to safeguard platelet, plasma and cryoprecipitate blood components against bacterial contamination, viruses and other pathogens for transfusion to patients; the system employs a photochemical treatment process using amotosalen and ultraviolet A light illumination, followed by the use of the INTERCEPT processing sets and accessories including platelet and plasma containers, illumination devices, and transfer sets. Core products include the INTERCEPT Blood System for platelets and plasma, approved by the FDA and bearing CE mark in Europe and available in the United States, Europe, the Middle East, the Commonwealth of Independent States, Latin America and other international markets through direct sales forces and distributors; the INTERCEPT Blood System for Cryoprecipitation, which produces Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex or IFC) approved in the US for treating bleeding associated with fibrinogen deficiency including massive hemorrhage; and the INTERCEPT Blood System for red blood cells, currently in late-stage clinical development. The company also offers implementation, training, technical support and maintenance services to facilitate adoption by blood centers and hospitals; it targets healthcare providers such as blood collection organizations, hospitals and ultimately patients reliant on safe transfusions within the biotechnology and medical devices sectors focused on transfusion medicine and blood safety. Recent developments include record third quarter 2025 results with raised full-year 2025 product revenue guidance driven by strong North American platelet growth, IFC business expansion and increased production capacity; an extended supply agreement with Porex Corporation effective January 1, 2025 through December 31, 2027 for platelet wafers and plasma disks ensuring supply chain stability with fixed pricing for the first two years; plans to launch an LED illuminator in Europe in 2025 and the US in 2026; a $248 million BARDA contract to advance the INTERCEPT red blood cell program; and a formal recommendation from the German National Blood Advisory Committee for enhancing platelet transfusion safety using pathogen reduction.
Cerus Corporation Closes New Debt Facility of Up to $110 Million
Bradley L. Radoff Announces Intent to Withhold Votes from Chair and CEO William Greenman and Director Ann Lucena
Cerus Corporation: Strong Q1 Results Validate The Turnaround Thesis
Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript
Cerus Corporation Announces First Quarter 2026 Financial Results
Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System
Critical Analysis: Akanda (NASDAQ:AKAN) and Cerus (NASDAQ:CERS)
Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026
Kevin Dennis Green Sells 127,544 Shares of Cerus (NASDAQ:CERS) Stock
Vivek Jayaraman Sells 165,200 Shares of Cerus (NASDAQ:CERS) Stock
Chrystal Jensen Sells 113,008 Shares of Cerus (NASDAQ:CERS) Stock
Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer
Cerus Details INTERCEPT Growth Plan, BCA Deal Upside and 2026 RBC Milestones at TD Cowen Conference
Cerus's Record 2025 Sets It Up For Another Leg Higher
Cerus Corporation (CERS) Q4 2025 Earnings Call Transcript
Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results
Cerus (NASDAQ:CERS) Stock Price Crosses Above 200-Day Moving Average – Should You Sell?
Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference
Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026
DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus' INTERCEPT™ Blood System in Routine Clinical Practice